Drug Trial Radar · NCT03325790
SPI-1005 for the Treatment of Patients With Meniere's Disease
Last checked: Nov 19, 2026Latest source record: Sep 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
149
Actual
Start
Sep 28, 2017
Primary completion
Apr 30, 2019
Study completion Apr 30, 2019
Sponsor
- Lead sponsor
- Sound Pharmaceuticals, IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Oct 30, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety, efficacy, and Pharmacokinetics (PK) of two dose levels of SPI-1005 administered for 28 days compared to placebo in patients with Meniere's disease.
Conditions
- Meniere's Disease
Interventions
200mg SPI-1005 BIDDrug
Active: low dose
400mg SPI-1005 BIDDrug
Active: high dose
PlaceboOther
Placebo Comparator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse Events (TEAE)Time frame: 8 weeks
- Efficacy of SPI-1005 on Hearing LossTime frame: 8 weeks
- Efficacy of SPI-1005 on Word Recognition ScoreTime frame: 8 weeks
- Efficacy of SPI-1005 on TinnitusTime frame: 8 weeks
- Efficacy of SPI-1005 on Tinnitus LoudnessTime frame: 8 weeks
- Efficacy of SPI-1005 on VertigoTime frame: 8 weeks
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Ccent/Cccr
Fresno, California
UCSD
San Diego, California
UCSF
San Francisco, California
Georgetown University
Washington D.C., District of Columbia
UMiami
Miami, Florida
KUMC
Kansas City, Kansas
Advanced ENT & Allergy
Louisville, Kentucky
ENT and Allergy Associates, LLP
New York, New York
CEENTA
Charlotte, North Carolina
TJU
Philadelphia, Pennsylvania
MUSC
Charleston, South Carolina
UT Southwestern
Dallas, Texas
Northwest Ear, Inc.
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.